4 results
DEF 14A
APGE
Apogee Therapeutics, Inc.
24 Apr 24
Definitive proxy
4:15pm
The amount of each NEO’s actual annual cash bonus was determined by the Board based on its assessment of each NEO’s individual performance as well as the Board’s assessment of overall company performance. Annual bonuses with respect to the 2023 Fiscal Year were approved by the Board in the following amounts:
NAME | | | 2023 ANNUAL CASH BONUS | | |||
Michael Henderson, M.D. | | | | $ | 606,375 | | |
Carl Dambkowski, M.D. | | | | $ | 393,750 | | |
Jane Pritchett Henderson | | | | $ | 374,332 | | |
DEF 14A
APGE
Apogee Therapeutics, Inc.
24 Apr 24
Definitive proxy
4:15pm
NAME AND PRINCIPAL POSITION | | | YEAR | | | SALARY ($) | | | BONUS ($)(2) | | | OPTIONS ($)(3) | | | STOCK AWARDS ($)(4) | | | ALL OTHER COMPENSATION ($)(5) | | | TOTAL ($) | | | |||||||||||||||||||||||
Michael Henderson, M.D. Chief Executive Officer | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||
| | | 2023 | | | | | $ | 564,833 | | | | | $ | 606,375 | | | | | $ | 7,500,000 | | | | | | — | | | | | | — | | | | | $ | 8,671,208 | | | | | | ||
| | | 2022(1) | | | | | $ | 145,833 | | | | | $ | 167,123 | | | | | | — | | | | | $ | 6,079,410 | | | | | $ | 56,750 | | | | | $ | 6,449,116 | | | | ||||
Carl Dambkowski, M.D. Chief Medical Officer | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||
| | | 2023 | | | | | $ | 477,083 | | | | | $ | 393,750 | | | | | $ | 3,300,000 | | | | | | — | | | | | | — | | | | | $ | 4,170,833 | | | | ||||
| | | 2022(6) | | | | | $ | 176,250 | | | | | $ | 212,932 | | | | | | — | | | | | $ | 1,194,638 | | | | | | — | | | | | $ | 1,583,820 | | | | ||||
Jane Pritchett Henderson(7) Chief Financial Officer | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||
| | | 2023 | | | | | $ | 469,311 | | | | | $ | 374,332 | | | | | $ | 3,300,000 | | | | | $ | 881,270 | | | | | | — | | | | | $ | 5,024,913 | | | |
10-K
2023 FY
APGE
Apogee Therapeutics, Inc.
5 Mar 24
Annual report
6:15am
| | | | | | | | | | | | | | | | | | | | |
| | | | | | | | STOCK | ALL OTHER | | | |||||||||
| | | | SALARY | | BONUS | | OPTIONS | | AWARDS | | COMPENSATION | | TOTAL | ||||||
NAME AND PRINCIPAL POSITION | | YEAR | | ($) | | ($)(2) | | ($)(3) | | ($)(4) | | ($)(5) | | ($) | ||||||
Michael Henderson, M.D. | | | | | | | ||||||||||||||
Chief Executive Officer | 2023 | | $ | 564,833 | | $ | 606,375 | | $ | 7,500,000 | | — | | — | | $ | 8,671,208 | |||
| 2022(1) | | $ | 145,833 | | $ | 167,123 | | — | | $ | 6,079,410 | | $ | 56,750 | | $ | 6,449,116 | ||
| | | | | | | | | | | | | | | | | | | | |
Carl Dambkowski, M.D. | | | | | | | | | ||||||||||||
Chief Medical Officer | 2023 | | $ | 477,083 | | $ | 393,750 | | $ | 3,300,000 | | — | | — | | $ | 4,170,833 | |||
| 2022(6) | | $ | 176,250 | | $ | 212,932 | | — | | $ | 1,194,638 | | — | | $ | 1,583,820 | |||
| | | | | | | | | | | | | | | | | | | | |
Jane Pritchett Henderson(7) | | | | | | | | | ||||||||||||
Chief Financial Officer | 2023 | | $ | 469,311 | | $ | 374,332 | | $ | 3,300,000 | | $ | 881,270 | | — | | $ | 5,024,913 |
10-K
2023 FY
APGE
Apogee Therapeutics, Inc.
5 Mar 24
Annual report
6:15am
| | | |
| 2023 ANNUAL CASH | ||
NAME | | BONUS | |
Michael Henderson, M.D. | | $ | 606,375 |
Carl Dambkowski, M.D. | | $ | 393,750 |
Jane Pritchett Henderson | | $ | 374,332 |
- Prev
- 1
- Next